Related Experiment Video

Updated: Sep 15, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.9K

Future Directions and Clinical Trial Considerations for Novel Islet β-Cell Replacement Therapies for Type 1 Diabetes

Marjana Marinac1, Michael R Rickels2, Jason L Gaglia3

  • 1Breakthrough T1D, New York, NY.

Diabetes
|July 15, 2025
PubMed
Abstract

Insights

Novel islet beta-cell replacement therapies offer more than rescue for unstable glucose. Expanding trials beyond severe hypoglycemia can achieve insulin-independent normoglycemia for type 1 diabetes patients.

Area of Science:

  • Endocrinology and Metabolism
  • Regenerative Medicine
  • Clinical Trial Design

Background:

  • Islet beta-cell replacement therapies are evolving beyond emergency treatments.
  • Current approaches primarily address unstable glucose management and severe hypoglycemia.

Purpose of the Study:

  • To advocate for broadening the application of islet beta-cell replacement therapies.
  • To emphasize the potential for achieving insulin-independent normoglycemia.
  • To highlight the need for patient-centered risk-benefit analysis in clinical trials.

Main Methods:

  • Review of current research and development in islet beta-cell replacement.
  • Analysis of clinical trial design considerations.
  • Evaluation of emerging safety data for cellular products, transplant sites, and immune protection.

Main Results:

  • Novel therapies show potential for insulin-independent normoglycemia.
  • Evidence for safety of various components is accumulating.
  • An increasing number of intervention options are becoming available.

Conclusions:

  • Islet beta-cell replacement therapies represent a paradigm shift, not just a rescue measure.
  • Clinical trials must expand eligibility criteria to include broader applications.
  • Informed, patient-centered decision-making is crucial as therapeutic options grow.

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

1.9K
Inguinal Subcutaneous White Adipose Tissue ISWAT Transplantation Model of Murine Islets10:14

Inguinal Subcutaneous White Adipose Tissue ISWAT Transplantation Model of Murine Islets

Published on: February 16, 2020

6.5K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
402
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
263
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
424